For industrial materials, the lowest quoted price is almost always the most expensive option. I've got six years of procurement data and 40-plus vendor relationships to back that up.
I’m a procurement manager at a 240-person electronics manufacturer serving automotive, medical device, and industrial customers. I’ve managed our direct materials budget — roughly $1.8 million annually — since 2019. I track every purchase order in our cost system, because guessing at material costs is how you end up paying twice for the same decision.
Here’s my argument: for industrial materials — silicone conformal coatings, gasket adhesives, magnet bonding adhesives — the unit price on the quote is a weak proxy for the cost you’ll actually pay. Three reasons follow. I’ll admit where my sample size limits the conclusion at the end.
Argument 1: The Material Is Not the Spec
We use Dow Corning 1-2577 conformal coating on about 60% of our boards. It’s not the cheapest option — we pay around $90 per liter from our authorized distributor. When we ran a re-sourcing exercise in Q2 2024, two alternatives came in $12–15 per liter cheaper.
That’s a projected savings of roughly $9,600 per year at our volume (~200 liters per quarter). Tempting.
Then I looked at what switching actually required. Both alternatives had different cure profiles (one needed 15 minutes longer at 120°C), different thermal expansion coefficients, and no existing qualification data for our IPC Class 2 boards. Re-qualifying a conformal coating meant:
- Thermal cycling tests (per IPC-CC-830): 2–3 weeks
- Adhesion testing on our actual substrate: 1 week
- Electrical insulation validation: 1 week
- Customer engineering-change approval: 2–4 weeks
I estimated the internal engineering hours at roughly $16,000 — plus the risk a customer rejects the change and we eat the cost. The “savings” wouldn’t break even for 18 months, and that’s before any field-failure risk.
So glad I didn’t just approve the cheaper quote. Almost signed off after the first savings estimate, which would have triggered a qualification cycle we didn’t need on a product that already works.
(And yes, I still check the Dow Corning logo on the label against our records before accepting a new batch. Gray-market material is real. Five minutes of traceability beats a failed batch with no paper trail.)
Argument 2: Gasket Adhesives and Magnet Bonding — Where “Cheap” Costs You Twice
Gasket adhesives and magnet bonding adhesives are smaller line items for us — combined maybe $55,000 annually. But they carry outsized failure costs.
We bond magnets into motor assemblies for an automotive customer. The adhesive we use is a one-part heat-cure silicone — nothing exotic. Last year a competitor quoted a cheaper alternative that looked spec-for-spec identical on paper. Same cure temperature, same shear strength on the datasheet.
What the datasheet didn’t show: a slightly different thermal expansion coefficient. In our application, the motor assembly goes through thermal cycling during operation. The mismatch would have created stress concentrations at the bond line. We found out because our test engineer runs a 500-cycle thermal shock test on any new adhesive before qualification — regardless of what the datasheet claims.
The cheaper adhesive failed at cycle 320 with partial delamination.
People assume higher prices cause higher quality. The causal arrow actually runs the other way: vendors who consistently deliver quality can charge more, because their products don’t fail under stress. If a vendor is charging 20% less than everyone else for the same “spec,” ask which part of the spec they aren’t telling you about.
From the outside, adhesive quotes look like apples-to-apples comparisons. Same cure time, same strength numbers. The reality is that datasheet specs cover a narrow window of conditions. Your application operates outside that window, and that’s where cheap materials fail.
Argument 3: Pharmaceutical Change Control — The Cost Multiplier Nobody Talks About
This one applies if you supply pharmaceutical customers or build equipment for pharma use. To understand what change control in pharma means in practice: it’s a formal, documented process where a regulated customer evaluates the impact of any material or supplier change before implementation — including regulatory filing implications.
We build components that end up in pharmaceutical manufacturing equipment. When a customer’s spec references a specific material — say, a Dow Corning gasket adhesive — any change triggers their change control process. I’ve seen a supplier swap trigger a 6-month review cycle at the customer site. Their internal cost — engineering review, validation testing, regulatory assessment — ran to roughly $40,000. That cost never appeared on our quote comparison. But it was the real reason the customer pushed back on the cheaper alternative.
I still kick myself for the time in 2022 when I swapped a supplier on a pharma-adjacent component without asking the customer’s quality team first. We caught it during their audit, but the corrective action plan took three months. If I’d picked up the phone before cutting the PO, I’d have saved everyone that headache.
Even something as simple as a brand transition can trigger it. When Dow Corning’s silicone business was folded into Dow after the 2016 acquisition, some of our material designations changed on the certificate of analysis. Same chemistry. Different supplier name. But for our pharma-adjacent customers, that was enough to reopen the validation file — two weeks of paperwork and a compliance addendum that cost both sides real time.
Granted, not every material purchase touches pharma change control. But if your customer’s industry is regulated, every supplier switch carries a hidden compliance cost. That cost lands on someone — and sometimes that someone is you.
The Pushback I Expect
I get why people push back here: budgets are real, and “TCO analysis” can sound like a dressed-up excuse for paying more. To be fair, sometimes the cheaper option is genuinely the right call. We buy commodity shop supplies on price all the time — if a material touches a non-critical application and a failure would cost almost nothing, the cheaper quote wins.
The distinction is avoidable risk. If a failure would cause a line stoppage, a customer complaint, or a regulatory issue, the expected cost of that failure dwarfs the per-unit savings. That’s not theoretical — I’ve tracked both directions.
My experience is based on about 200 mid-range industrial orders across electronics and automotive applications. If you’re buying commodity materials in huge volumes or working in a highly specialized niche, your numbers will differ. But the framework holds: before you pick the cheaper quote, calculate what happens if it fails.
The Point I Keep Coming Back To
The lowest unit price on a quote is a starting point, not the answer. I’ve run into this pattern often enough to trust it: when a vendor quotes 15–20% below the field for industrial materials, the cost hasn’t disappeared — it’s moved somewhere you can’t see yet. Maybe it’s hidden in labor. Maybe it’s a qualification cycle. Maybe it’s a change control process your customer will bill you for.
The vendors I trust most aren’t the cheapest ones. They’re the ones whose quotes I can compare with confidence, because everything I’ll actually pay is on the page.
(Note to self: finally build that TCO template for small-quantity orders. We keep skipping them because they’re “too small to matter,” but the aggregate cost of those decisions is real — and I’d rather find out now than at the next budget review.)